AI-generated analysis. Always verify with the original filing.
Enzon Pharmaceuticals, Inc. issued a press release on March 25, 2026, announcing the completion of the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock. The press release is attached as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure and is not deemed filed under the Exchange Act.
Event Type
Disclosure
Voluntary
Variant
8-K
Regulation FD Disclosure. On March 25, 2026, Enzon Pharmaceuticals, Inc. issued a press release announcing the completion of the exchange offer relating to its
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release issued by Enzon Pharmaceuticals, Inc., dated March 25, 2026 (incorporate